Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Depomed’s Glumetza Q3 Launch Will Be Executed By King

This article was originally published in The Pink Sheet Daily

Executive Summary

Commercialization agreement gives King rights to market extended-release metformin in the U.S., while Depomed retains co-promotion rights.

You may also be interested in...



Depomed Takes ProQuin XR Rights Back From Esprit

Firm will leverage its Glumetza commercial structure to sell and distribute the proprietary ciprofloxacin formulation in the U.S.

Depomed Takes ProQuin XR Rights Back From Esprit

Firm will leverage its Glumetza commercial structure to sell and distribute the proprietary ciprofloxacin formulation in the U.S.

King Specialty Cardiovascular/Metabolics Force To Be In Place By September

Second quarter Altace sales up $10 mil. as Wyeth co-promotion winds down.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS064410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel